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Background: Dengue has been designated a major international public health problem by the World Health
Organization. It is endemic in most tropical and sub-tropical countries, which are also popular tourist destinations.
Travelers are at significant risk of acquiring the disease and also contribute to its spread to non-endemic countries
where the vector is present. Children represent a particular susceptible category, since they have a higher risk than
adults of developing severe dengue.
Case presentation: We describe 3 cases of imported dengue fever in Italy in three children (two born in the
Philippines and one of Bangladeshi ethnicity) who acquired dengue fever during a recent travel to Southeast Asia,
initially not-recognized because of the low index of suspicion of physicians not working in dengue endemic areas.
Clinical presentations, differential diagnosis and management of these children are presented and discussed.
Conclusions: Due to global urbanization and increased air travel, it is nowadays important that physicians who
practice outside of traditionally dengue endemic areas are adept at the recognition of potentially fatal reemerging
infectious diseases such as dengue.
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Dengue has been designated a major international public
health problem by the World Health Organization
(WHO). It is endemic in most tropical and sub-tropical
countries, which are also popular tourist destinations.
Travelers are at significant risk of acquiring the disease
and also contribute to its spread to non-endemic coun-
tries [1]. They may further serve as sentinels to alert the
international community to epidemics in dengue-endemic
regions and to the spread of dengue virus serotypes and
genotypes [2]. Children represent a particular susceptible
category, since they have a higher risk than adults of de-
veloping severe dengue (up to 10% cases) [3].
We describe 3 cases of imported dengue fever in Italy
in three children who acquired Dengue fever during a
travel to Southeast Asia in 2013. The purpose of this
report is to review current literature regarding the
epidemiology, clinical manifestations, diagnosis, and
management of this important, still unrecognized global* Correspondence: danilobuonsenso@gmail.com
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A previously healthy 10-year-old boy born in the
Philippines presented to a pediatric emergency depart-
ment with a 3-day history of fever (max temperature
39.6°C), generalized malaise, severe headache, vomiting
and weight loss. His parents reported that the baby had
been in the Philippines to meet his grandparents and
was back in Italy since 5 days. On admission, the patient
was alert and had a temperature of 39.9°C, heart rate of
110 beats per minute, respiratory rate of 20 breaths per
minute, and a blood pressure of 104/60 mm Hg. Physical
examination revealed a suffering teenager with a mild
macula-papular rash, rigor nucalis, severe back pain and
myalgia, abdominal tenderness and retro-orbital pain
during eye movements. He did not have lymphade-
nopathy, or visceromegaly. Laboratory data included a
white blood cell count of 6800/mL (with 82% neutro-
phils, 8% lymphocytes, and 10% monocytes), hemoglobin
level of 12.8 g/dL, platelet count of 214,000/mm3, antral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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aminotransferase level of 196 U/L, C-reactive protein of
38 mg/dL (normal value < 0.5 mg/dl). Serum urea nitro-
gen and electrolytes, serum creatinine, urinalysis and
coagulation studies were within reference limits. Chest
X-ray was normal. Lumbar puncture was performed due
to a suspected central nervous system infection, but
cerebrospinal fluid indices were normal. Head computed
tomography (CT) was negative. Thick and thin stained
blood smears were negative for malaria. The parents re-
ported that dengue hemorrhagic fever (DHF) was on-
going in the Philippines. At this point, a blood specimen
for dengue fever serology and reverse transcription-
polymerase chain reaction was submitted to the Italian
National Institute of Health and the patient was trans-
ferred to the Pediatric Infectious Disease Unit of our
Institution. Due to the potential exposition to a dengue
fever epidemics, this diagnosis was considered as the
most probable. Nevertheless, differential diagnosis at this
time still included viral syndrome, meningococcemia,
and Rocky Mountain spotted fever (RMSF). Serology
for Epstein-Barr virus (EBV), Cytomegalovirus (CMV),
coxsackie virus, echovirus, hepatitis A virus, RMSF,
Ehrlichia chaffeensis, and Coxiella burnetti were performed.Figure 1 Schematic representation of main laboratory tests performe
E: transaminasis (sGPT/ALT).The fever had continued for 4 days and subsided on the
second day of hospitalization. On the second day of ad-
mission, one episode of coffee ground vomiting developed,
thrombocytopenia proceeded to 50000/mm3 at the mini-
mum on day 6, the white blood cell count exhibited a
minimum of 1,800/dL on day 5 (400 neutrophils/dL), and
all these parameters began to rise on day 8 of illness.
Haematocrit peaked up to 40% on day 6 and decreased to
36% on day 10. The transaminase level peaked on days 5
to 8 of his illness (both aspartate aminotransferase and
alanine aminotransferase level up to 250 IU/L) (Figure 1).
Urine output, blood pressure and heart rate remained al-
ways within normal ranges. Results of serology for EBV,
CMV, RMSF, Ehrlichia chaffeensis, and Coxiella burnetti
were all negative. Cerebrospinal fluid, blood, fecal, and
urine cultures were sterile. Result of throat viral culture
was negative. A recent dengue infection was confirmed by
demonstration of immunoglobulin M (IgM) antibody and
positive RT-PCR for dengue virus type 2 and intravenous
ceftriaxone and acyclovir were discontinued. Intravenous
fluid therapy was stopped when the recovery of appetite,
decrease in hematocrit and increase in platelet count was
observed. The child gradually improved, bradicardia de-
veloped (up to 50 bpm) and was discharged on the tenthd to patient 1. A: hematocrit; B: platelets; C: white cells; D: neutrophils;
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patient was well appearing with resolution of throm-
bocytopenia, leukopenia, and hepatitis.
Case 2
The second case was a 1-year-old Bangladeshi girl who
visited her relatives in Bangladesh in October 2012. Du-
ring the last days before coming in Italy she suffered
from fever (39°C), myalgias and nausea and was diag-
nosed with dengue virus infection in her birth country.
Due to an uncomplicated disease, the girl was not admit-
ted to the hospital and the girl and her family took the
flight to Italy. Four days later, due to persistence of high-
grade fever, she presented to the emergency ward in our
hospital and admitted to the pediatric infectious disease
unit. On admission, the body temperature was 38°C,
physical examination was normal. Blood cultures were
negative for bacteria and malaria was ruled out by
microscopic blood examination. Serology was positive
for dengue virus (via enzyme-linked immunosorbent
assay [ELISA]). Serology for human immunodeficiency
virus (HIV) infection, acute hepatitis A, B and C, CMV
and EBV were negative. Haematocrit, white-blood cell,
platelet count, and liver-function tests remained always
normal. The girl was able to retain oral fluids and diu-
resis was valid. The girl had non-complicated dengue
fever, according to the new classification of the World
Health Organization [4].
Case 3
The third case was a 9-year-old Philippine girl resident
in Italy, who went for holiday with her family to the
Philippines. During her stay in the Philippines she deve-
loped high grade fever (up to 39.5°C), treated with para-
cetamol for three days with benefit, and diarrhea. On
the fourth and fifth day she developed epistaxis and was
brought to the emergency room in her birth country
were dengue virus infection was diagnosed. The day
after, despite the persistence of fever, the girl and the
family took the flight to come back in Italy. Due to the
persistence of fever on the sixth day, the family took the
girl to the emergency room of our hospital. On admis-
sion, the girl appeared in good clinical condition, the
body temperature was 37.8°C, physical examination was
normal. The girl had signs of mild dehydration. La-
boratory data included a white blood cell count of
8630 cells/ml (with 69.8% neutrophils, 21.3% lymphocytes
and 8.6% monocytes), hemoglobin level of 12.6 g/dL,
platelet count of 175.000/mm3, C-reactive protein of
3.54 mg/dl (normal value < 0.5 mg/dl). Serum urea nitro-
gen and electrolytes, serum creatinine, aminotransferases,
urinalysis and coagulation studies were within reference
limits. Chest X-ray was normal. The patient was then ad-
mitted to the Pediatric Infectious Disease Unit of ourInstitution and intravenous fluids were started. Due to a
recent travel to a dengue-endemic country, a blood speci-
men for dengue fever serology and reverse transcription-
polymerase chain reaction was submitted to the Italian
National Institute of Health, which turned positive for
dengue virus type 2. During hospitalization haematocrit,
white-blood cell, platelet counts and liver-function tests
remained always normal. Fever subsided on the 8th day of
illness. Urine output, blood pressure and heart rate re-
mained always within normal ranges for age. The girl did
not present new hemorrhagic episodes and was able to
tolerate oral intake since the second day of admission and




Dengue fever is an acute viral illness transmitted most
commonly by Aedes aegypti mosquitoes, which is endemic
in tropical Asia, Latin America, and the Caribbean [5].
Dengue is the most rapidly spreading mosquito-borne
viral disease in the world. In the last 50 years, incidence
has increased 30-fold with increasing geographic expan-
sion to new countries and, in the present decade, from
urban to rural settings. An estimated 50 million dengue
infections occur annually and approximately 2.5 billion
people live in dengue endemic countries [6]. Because of
global urbanization with substandard living conditions, in-
creased mobility of populations, ineffective vector control,
viral and vector evolution, and climate change, dengue has
become a major public health challenge in the past half
century [7]. In Italy, a recent retrospective study identified
dengue infection in 15 out of 91 travelers from endemic
areas (16.5%) [8]. This high rate of imported dengue infec-
tion in Italy, as well as in other temperate European and
non European countries, where dengue virus is not en-
demic, is of particular concern since increased mobility of
populations, substandard living conditions, ineffective vec-
tor control, viral and vector evolution, and climate change
could modify the present situation [9]. The alternative
dengue vector, Aedes albopictus, seems to be spreading
into temperate climates, potentially worsening the global
dengue problem [5]. In Italy, for example, the dengue vec-
tor Aedes albopticus is represented in the Po river valley
in the North West Italy, where imported cases have been
recently described [8]. Children represent a significant
proportion of the travelling public, accounting for 7%
(1.9 million) of travelers living in the US [9]. Classic and
severe dengue in children pose a significant burden on en-
demic countries [10]. A study of over 1500 ill pediatric
travelers reporting to GeoSentinel Clinics in 19 countries
identified dengue and typhoid fever as the most frequent
causes of systemic febrile illness in children returning
from tropical regions other than sub-Saharan Africa.
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vere dengue, a leading cause of morbidity and death in
this age-group [3], mainly for a secondary infection in
which the mortality rate is nearly 15-fold higher than in
adults [2,11].
Clinical manifestations and management
The clinical manifestations of dengue fever are varied
[5]. After an incubation period of 3 to 14 days, the indi-
vidual may be asymptomatic or may present with mild
undifferentiated fever to severe disease that includes
hemorrhagic and hypovolemic shock [2,5]. Nevertheless,
bleeding manifestations may be present in approximately
10% of cases of uncomplicated dengue fever, therefore
the WHO proposed a new classification in 2009, which
reclassifies dengue into dengue with or without warning
signs and severe dengue (Additional file 1: Table S1) [4].
As reported in Additional file 1: Table S2, the
disease course of DHF is classically divided into three
phases: febrile, plasma leakage (critical), and convales-
cent (recovery) phases [12].
The first phase presents with influenza-like illness with
sudden onset of high-grade fever, retro-orbital pain, se-
vere headache, myalgia, arthralgia, and rash in approxi-
mately 50% of cases [5,13]. Because of the presenting
symptoms of severe myalgias, arthralgia, and fever, den-
gue fever was referred to as breakbone fever during
World War II in India and Burm [14]. In this phase, as
showed in case 1, differential diagnosis is wide. Despite
the doctor was aware that the child recently travelled
from Philippines to Italy, he did not think about travel-
related illnesses and suspected a meningo-encephalitis,
performing a lumbar puncture and head CT scan and
beginning antibiotic and antiviral therapy. Dengue fever
was suspected only when the mother reported an on-
going dengue epidemics in the Philippines. This point
underlines the importance of always considering dengue
fever in febrile travelers from endemic areas. During this
phase, once dengue fever is suspected, on the basis of
medical history, physical examination and full blood
count and haematocrit, clinicians should be able to de-
termine whether the disease is dengue, which phase it is
in, whether there are warning signs, the hydration and
hemodynamic status of the patient, and whether the pa-
tient requires admission to the hospital. To strengthen
the importance of anamnesis and clinical symptoms of
children suffering from dengue fever here we report the
Additional file 1: Table S3.
During the febrile phase, patients who are able to
tolerate adequate volumes of oral fluids and pass urine
at least once every six hours, and do not have any of the
warning signs, particularly when fever subsides, may not
be admitted if the family is compliant, but should be
reviewed daily for disease progression (decreasing whiteblood cell count, and warning signs) until they are out
of the critical period. Those with stable haematocrit can
be sent home, but, because of concerns about family
compliance, we admitted to the hospital the girl of case
2 till complete resolution of dengue fever. These patients
are classified as having non complicated dengue fever, as
happened to the girl in case 2. Anyway, doctors dealing
with a case of non complicated dengue fever should [12]
– Encourage oral intake of oral rehydration solution
(ORS), fruit juice and other fluids containing
electrolytes and sugar to replace losses from fever
and vomiting.
– Give paracetamol for high fever if the patient is
uncomfortable, avoiding acetylsalicylic acid,
ibuprofen or other non-steroidal anti-inflammatory
agents (NSAIDs) as these drugs may aggravate
gastritis or bleeding.
– Instruct the care-givers that the patient should be
brought to hospital immediately if any of the
following occur: no clinical improvement,
deterioration around the time of defervescence,
severe abdominal pain, persistent vomiting,
cold and clammy extremities, lethargy or irritability/
restlessness, bleeding (e.g. black stools or
coffee-ground vomiting), not passing urine for
more than 4–6 hours.
– As showed in case one, severe pain is usually one of
the main symptoms of dengue fever in children. In
case paracetamol would not be sufficient for pain
control, some authors have demonstrated the safety
and efficacy of intravenous fentanyl administered by
“patient controlled anesthesia” plus background
infusion in children [15].
Around the time of defervescence, when the tem-
perature drops to 37.5–38°C or less and remains below
this level, usually on days 3–7 of illness, an increase in ca-
pillary permeability in parallel with increasing haematocrit
levels may occur [7,8]. This marks the beginning of the
critical phase. The period of clinically significant plasma
leakage usually lasts 24–48 hours [4]. The child in case 1
had advanced to the plasma leakage phase on day 5, when
he developed hemoconcentration, thrombocytopenia and
leucopenia and bleeding tendencies (coffee ground vo-
miting). This is a critical teaching point, since clinicians
must be aware that the massive capillary leak syndrome is
usually noted soon after the patient is not anymore febrile
(days 3 to 6), as happened in case 1, so the abrupt reso-
lution of fever (and the apparent improvement of clinical
conditions) is an indication for closer monitoring, not for
discharge. A drop in platelets, accompanied or followed
by a rise in hematocrit, is a worrisome finding and may
precede the onset of shock. Abdominal pain, persistent
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impending shock. Hematocrit levels should be mea-
sured from day 3 until the patient has been afebrile for
1 to 2 days, at which time the risk of progression to
shock is low. Critical points for the management of this
phase are [4]:
– Give paracetamol for high fever if the patient is
uncomfortable. The interval of paracetamol dosing
should not be less than six hours. Do not give
acetylsalicylic acid (aspirin), ibuprofen or other
non-steroidal anti-inflammatory agents (NSAIDs) as
these drugs may aggravate gastritis or bleeding.
– Clinical status and hematocrit need to be
continuously monitored, in order to continuously
review intravenous fluid therapy during the critical
phase and once hemodynamic status has stabilized,
to promptly recognize and treat the onset of shock,
or to recognize the potential complication of fluid
overload.
– Obtain a reference haematocrit before fluid therapy.
Give only isotonic solutions such as 0.9% saline,
Ringer’s lactate, or Hartmann’s solution. Start with
5–7 ml/ kg/hour for 1–2 hours, then reduce to
3–5 ml/kg/hour for 2–4 hours, and then reduce to
2–3 ml/kg/hour or less according to the clinical
response.
– Reassess the clinical status and repeat the
haematocrit. If the haematocrit remains the same or
rises only minimally, continue with the same rate
(2–3 ml/kg/hour) for another 2–4 hours. If the vital
signs are worsening and haematocrit is rising rapidly,
increase the rate to 5–10 ml/kg/hour for 1–2 hours.
Reassess the clinical status, repeat the haematocrit
and review fluid infusion rates accordingly.
– Give the minimum intravenous fluid volume required
to maintain good perfusion and urine output of about
0.5 ml/kg/hr. Intravenous fluids are usually needed for
only 24–48 hours. Reduce intravenous fluids gradually
when the rate of plasma leakage decreases towards the
end of the critical phase. This is indicated by urine
output and/or oral fluid intake that is/are adequate, or
haematocrit decreasing below the baseline value in a
stable patient.
– Patients with warning signs should be monitored by
health care providers until the period of risk is over. A
detailed fluid balance should be maintained. Parameters
that should be monitored include vital signs and
peripheral perfusion (1–4 hourly until the patient is out
of the critical phase), urine output (4–6 hourly),
haematocrit (before and after fluid replacement, then
6–12 hourly), blood glucose, and other organ functions
(such as renal profile, liver profile, coagulation profile,
as indicated).Also the girl in case 3 presented dengue fever with
warning signs, since she presented mucosal bleeding for
two days; nevertheless, differently from the child in case 1,
girl in case 3 improved earlier and did not present a drop
in platelet count and a rise in hematocrit after fever reso-
lution. Despite adequate management, patients can pro-
gress to severe dengue fever (critical phase). All patients
with severe dengue should be admitted to a hospital with
access to intensive care facilities and blood transfusion.
The recovery phase begins if the patient survives the
24–48 hour critical phase. General well-being improves,
appetite returns, gastrointestinal symptoms abate, hemo-
dynamic status stabilizes and diuresis ensues [4]. As
shown in case 1, intravenous fluids were stopped when
the child recovered appetite; this is a critical teaching
point for the management of patients in the “recovery
phase”, since a potential complication of this phase of
dengue fever is hypervolaemia if intravenous fluid therapy
has been excessive and/or has extended into this period.
Despite fluid therapy is the mainstay of the management
of dengue fever, a detailed description of doses and type of
fluids to use in every moment of each phase or complica-
tion of dengue fever is not the purpose of this work, but
readers can refer to WHO 2009 guidelines for these de-
tails [4]. What we think is particularly important for every
pediatrician is the knowledge of some key clinical points,
which are summarized in the following “good and bad
clinical practice” table for the management of dengue
fever, adapted from WHO 2009 guidelines (Additional
file 1: Table S4).
Diagnosis
The diagnosis of dengue fever is confirmed by serologic
tests defined by a 4-fold increase in acute - and convales-
cent – phase anti-dengue IgG titers or detection of IgM to
dengue virus. Culture of the virus is technically difficult.
Amplification of dengue RNA by reverse transcription-
polymerase chain reaction is available in research settings
for confirmation and surveillance [16]. Because a definitive
laboratory diagnosis of dengue fever takes more than a
week, a clinical diagnosis must be made after ruling out
other infectious diseases and empiric therapy started, as
happened in case 1. Because the incubation period of
dengue is between 3 and 14 days, fever beginning more
than 2 weeks in a returned traveler after leaving an
endemic region rules out the diagnosis of dengue infection
(14). Infection with an individual virus provides per-
manent immunity to that serotype, but no immunity is
conferred to the other serotypes [2,5,14].
Prevention - Vaccine
There is currently no licensed dengue vaccine, and mea-
sures such as vector control are proving inadequate in re-
ducing the incidence of the disease [17]. Therefore, with
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against dengue is limited to avoidance of mosquito bites
with the use of insect repellents, protective clothing and
insecticides [2,18]. While this could be performed in
endemic areas particularly during epidemics, it could be
difficult to routinely perform vector prevention measures
in non endemic areas. The case of the epidemic outbreak
of Chikungunya virus (CHIKV) infection in a narrow area
of the Romagna region in northern Italy is a key lesson on
this regard [19]. The initial source transmission was iden-
tified in an Indian immigrant resident in Romagna who
returned from his home country in late June 2007 during
the viremic asymptomatic stage of the infection. The
extremely large population of A.albopictus present in this
region precipitated the local transmission. A total of 248
cases were identified over a geographical area that was en-
larged to most of the Romagna region (including a small 5
cases cluster in the regional capital city of Bologna located
some 70 kilometers away from the origin of the epidemic).
The epidemic of CHIKV infection that occurred in north-
ern Italy constitutes a new model for the diffusion of a
tropical disease outside the conventional locations. The
outbreak mainly resulted from the “dangerous mixture” of
the large population of a highly competent vector, the
tiger mosquito, and the possibility that an individual
returned from an area of normal diffusion of CHIKV
during the asymptomatic viremic stage of infection.
Considering the difficulties in controlling the spread of
A. albopictus and the large population travelling to and
from the areas of normal diffusion of vector-borne trop-
ical diseases we think that the 2007 epidemic may be only
the first of a possible series of these outbreaks [19]. What
happened with CHIKV could happen with dengue virus
too, since the vector of Dengue virus is diffused in Italy
too and the high rate of international travels from dengue
endemic countries could easily introduce the virus in non
endemic areas. It is particularly worrisome that 2 out of
the 3 children we evaluated were already diagnosed with
dengue in their birth country and decided to take the
flight and fly to Italy during the febrile, viremic stage of
the disease, with the potential of local transmission in case
of presence of large population of dengue vector in the
destination area, such as Italy. This highlights a new possi-
bility for dengue control: it could be a measure of control
introducing an airport gate at least during epidemic sea-
sons. Probably, feverish patients or at least those with a
known diagnosis of dengue disease should not be allowed
to take plane, at least those directed in area with the po-
tential of local transmission due to the presence of vector,
such as Italy. In fact, models describing the temporal dy-
namics of the Aedes albopictus coupled to an epidemic
transmission model describing the spread of the epidemic
in both humans and mosquitoes have widely supported
the hypothesis that outbreaks of CHIKV and similarviruses in those temperate climate countries characterized
by high density of Aedes albopictus are probable after the
importation of an index case from abroad [20]. Due to all
these difficulties in epidemiological control of dengue
infection, an effective and cost-effective vaccine against
dengue would therefore be a major advance in controlling
the disease [21]. Given the high incidence of the disease in
travelers, a vaccine for them may also be indicated, pro-
vided that it is safe, convenient to administer and affor-
dable [22]. The vaccine candidate furthest in development
is a chimeric vaccine by Sanofi Pasteur. With the lead
candidate vaccine showing encouraging results in late-
stage clinical trials, the outlook for introduction of a
vaccine against all four dengue serotypes into national
immunization programmes of endemic countries is pro-
mising [2,23].
Conclusions
Global urbanization and increased air travel necessitates
the ability of physicians who practice outside of tra-
ditionally dengue endemic areas to become adept at the
recognition of potentially fatal reemerging infectious
diseases such as dengue. Dengue infection should be in-
cluded in the differential diagnosis of patients with fe-
brile illness with a history of recent travel to endemic
regions. Furthermore, travelers contribute to the geo-
graphic spread of dengue and its introduction to previ-
ously uninfected areas. The rising numbers of dengue
cases reported worldwide, the resurgence of A. aegypti
in the Western Hemisphere, such as Italy, and the iden-
tification of locally acquired dengue infections in non-
endemic regions, emphasize the need for surveillance of
travelers returning from endemic areas. Early detection
and management of severe disease is critical to prevent
morbidity and mortality [24]. Due to the global diffusion
of dengue virus, dengue cannot anymore be considered
a disease localized only in some endemic countries, but
it has to be considered a global disease that every phy-
sician could deal with during his career. Therefore, on
the basis of evaluations of the history, physical exami-
nation and/or full blood count and haematocrit, all clini-
cians despite their specialty should be able to determine
whether the disease is dengue, which phase it is in
(febrile, critical or recovery), whether there are warning
signs, the hydration and hemodynamic status of the pa-
tient, and whether the patient requires admission to the
hospital.
Consent
Written informed consent was obtained from the pa-
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